49.53 +0.22 (0.46%)
Pre-Market: 4:17AM EDT
|Bid||49.58 x 2400|
|Ask||49.62 x 3000|
|Day's Range||49.18 - 49.85|
|52 Week Range||30.89 - 49.85|
|PE Ratio (TTM)||20.34|
|Dividend & Yield||0.95 (1.93%)|
|1y Target Est||N/A|
GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, a preliminary review by the U.S. Food and Drug Administration concluded, sending the company's shares up 3.4 percent in premarket trading on Monday. The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of advisors to the agency who will discuss the drug, semaglutide, and recommend whether it should be approved. The FDA typically follows the recommendations of its advisors.
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.
The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.
Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.
The U.S. Food and Drug Administration on Friday approved Novo Nordisk's fast-acting insulin to treat diabetes. The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. Fiasp, or faster acting insulin asparte, is designed to work faster than existing fast-acting insulin such as Eli Lilly and Co's Humalog and Novo Nordisk's own NovoLog, known as NovoRapid outside the United States.
Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.
In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.
In the first half of 2017, Novo Nordisk’s (NVO) Victoza generated revenues of DKK (Danish kroner) 11.5 billion, which reflected a ~21.0% rise on a YoY (year-over-year) basis.
In the first half of 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of DKK (Danish kroner) 284.0 million.
In the first half of 2017, Novo Nordisk’s (NVO) NovoRapid generated revenues of DKK (Danish kroner) 10.4 billion, which reflected a 9.0% rise on a YoY (year-over-year) basis.
In June 2017, Novo Nordisk (NVO) presented results from the DEVOTE trial, which was conducted to evaluate the safety and efficacy of Tresiba.
In the first half of 2017, Novo Nordisk’s new generation insulins reported revenues of DKK (Danish kroner) 4.2 billion compared to DKK 1.6 billion in the first half of 2016.
In the first half of 2017, Novo Nordisk (NVO) reported revenues of $8.3 billion compared to $8.2 billion in the first half of 2016. In 2Q17, it generated revenues of $4.2 billion.
Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock is off more than 50% so far this year. This is one of the leading generic drug producers in the world. Unfortunately, U.S. courts changed the dynamic by allowing more generics competition sooner than TEVA counted on.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Novo Nordisk A/S with the following peers – Pfizer Inc., Roche Holding Ltd Genusssch., Bristol-Myers Squibb Company, Eli Lilly and Company and Sanofi Sponsored ADR (PFE-US, RHHVF-US, BMY-US, LLY-US and SNY-US). Novo Nordisk A/S’s dividend yield is 1.69 percent and its dividend payout is 35.96 ... Read more (Read more...)
Rating Action: Moody's Affirms Seven Classes of WFCM 2016- NXS6. Global Credit Research- 15 Sep 2017. Approximately $574 Million of Structured Securities Affected.
Teva rocketed Monday after announcing a former Novo Nordisk executive will take the helm at Teva, just seven months after its last full-time CEO resigned.
Kare Schultz will be taking over the position of president and CEO at Teva Pharmaceutical Industries Ltd (ADR). This will have him replacing Dr. Yitzhak Peterburg, who has been serving the company as its Interim CEO. Kare Schultz was chosen as the new CEO of Teva Pharmaceutical Industries Ltd (ADR) by its Board of Directors.
Teva Pharmaceutical Industries Ltd ADR (NYSE:TEVA) named Kåre Schultz to become the president and CEO, according to a company press release today. Schultz is viewed as a seasoned veteran in the healthcare industry, with more than 30 years experience in global pharmaceutical and healthcare companies.
Last summer, the diabetes-focused pharmaceutical issued distressing guidance due to pricing pressure worries, but the forecast troubles failed to arrive.